CA2231105C
(en)
*
|
1995-12-08 |
2005-09-13 |
Janssen Pharmaceutica N.V. |
Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quinolinone derivatives
|
PT988038E
(pt)
*
|
1997-06-02 |
2002-12-31 |
Janssen Pharmaceutica Nv |
Derivados (imidazol-5-il)metil-2-quinolinona como inibidores da proliferacao de celulas dos musculos lisos
|
US20030114503A1
(en)
*
|
1997-06-16 |
2003-06-19 |
Pfizer Inc. |
Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the treatment of cancer
|
JP2002518387A
(ja)
*
|
1998-06-16 |
2002-06-25 |
ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス |
イミダゾリル誘導体
|
US6420555B1
(en)
|
1998-06-16 |
2002-07-16 |
Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. |
Imidazolyl derivatives
|
DK1094839T3
(da)
*
|
1998-07-06 |
2003-08-18 |
Janssen Pharmaceutica Nv |
Farnesylproteintransferaseinhibitorer med in vivo radiosensibiliserende egenskaber
|
EE04579B1
(et)
*
|
1998-07-06 |
2006-02-15 |
Janssen Pharmaceutica N.V. |
Farnesüülproteiintransferaasi inhibiitorite kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on ette nähtud artropaatiate raviks
|
FR2780892B1
(fr)
*
|
1998-07-08 |
2001-08-17 |
Sod Conseils Rech Applic |
Utilisation d'inhibiteurs de prenyltransferases pour preparer un medicament destine a traiter les pathologies qui resultent de la fixation membranaire de la proteine g heterotrimerique
|
BR9913315A
(pt)
*
|
1998-08-27 |
2001-05-22 |
Pfizer Prod Inc |
Derivados de quinolin-2-ona úteis como agentes anticâncer
|
AU4925499A
(en)
*
|
1998-08-27 |
2000-03-21 |
Pfizer Products Inc. |
Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents
|
WO2000034437A2
(en)
|
1998-12-08 |
2000-06-15 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
WO2000034239A2
(en)
|
1998-12-08 |
2000-06-15 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
WO2000039082A2
(en)
|
1998-12-23 |
2000-07-06 |
Janssen Pharmaceutica N.V. |
1,2-annelated quinoline derivatives
|
JP3270834B2
(ja)
|
1999-01-27 |
2002-04-02 |
ファイザー・プロダクツ・インク |
抗がん剤として有用なヘテロ芳香族二環式誘導体
|
UA71945C2
(en)
|
1999-01-27 |
2005-01-17 |
Pfizer Prod Inc |
Substituted bicyclic derivatives being used as anticancer agents
|
CN1340051A
(zh)
|
1999-02-11 |
2002-03-13 |
辉瑞产品公司 |
可用作抗癌剂的杂芳基取代的喹啉-2-酮衍生物
|
US6143766A
(en)
*
|
1999-04-16 |
2000-11-07 |
Warner-Lambert Company |
Benzopyranone and quinolone inhibitors of ras farnesyl transferase
|
EP1420015A1
(en)
*
|
1999-06-11 |
2004-05-19 |
Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. |
Imidazolyl derivatives
|
FR2796943A1
(fr)
*
|
1999-07-30 |
2001-02-02 |
Aventis Pharma Sa |
Derives de benzoxazinnes, leur procede de preparation et leur utilisation en therapeutique
|
JP2003513940A
(ja)
*
|
1999-11-09 |
2003-04-15 |
ソシエテ・ド・コンセイユ・ド・ルシエルシエ・エ・ダアツプリカーション・シヤンテイフイツク・(エス.セー.エール.アー.エス) |
ヘテロ三量体gタンパク質情報の伝達抑制剤と他の抗癌剤とからなる、癌の処置において治療の目的に使用する製品
|
PT1106612E
(pt)
*
|
1999-11-30 |
2004-06-30 |
Pfizer Prod Inc |
Derivados de quinolina uteis para inibir a farnesil-proteina-transferase
|
HN2000000266A
(es)
*
|
2000-01-21 |
2001-05-21 |
Pfizer Prod Inc |
Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
|
ES2262626T3
(es)
*
|
2000-02-04 |
2006-12-01 |
Janssen Pharmaceutica N.V. |
Inhibidores de farnesil proteina transferasa para tratar cancer de mama.
|
CA2397558A1
(en)
*
|
2000-02-24 |
2001-08-30 |
Janssen Pharmaceutica N.V. |
Dosing regimen
|
JP2003525239A
(ja)
*
|
2000-02-29 |
2003-08-26 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
タキサン化合物とのファルネシルタンパク質トランスフェラーゼ阻害剤の組み合わせ剤
|
AU2001244166A1
(en)
*
|
2000-02-29 |
2001-09-12 |
Janssen Pharmaceutica N.V. |
Farnesyl protein transferase inhibitor combinations with further anti-cancer agents
|
WO2001064196A2
(en)
*
|
2000-02-29 |
2001-09-07 |
Janssen Pharmaceutica N.V. |
Farnesyl protein transferase inhibitor combinations with vinca alkaloids
|
CA2397694A1
(en)
*
|
2000-02-29 |
2001-09-07 |
Janssen Pharmaceutica Inc. |
Farnesyl protein transferase inhibitor combinations
|
CA2397446A1
(en)
*
|
2000-02-29 |
2001-09-07 |
Janssen Pharmaceutica Inc. |
Combinations of a farnesyl protein transferase inhibitor with nitrogen mustard or nitrosourea alkylating agents
|
US20030100553A1
(en)
*
|
2000-02-29 |
2003-05-29 |
Palmer Peter Albert |
Farnesyl protein transferase inhibitor combinations with camptothecin compounds
|
JP2003525252A
(ja)
*
|
2000-02-29 |
2003-08-26 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
Her2抗体とのファルネシルタンパク質トランスフェラーゼ阻害剤組み合わせ剤
|
AU2001244167A1
(en)
*
|
2000-02-29 |
2001-09-12 |
Janssen Pharmaceutica N.V. |
Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
|
WO2001064198A2
(en)
*
|
2000-02-29 |
2001-09-07 |
Janssen Pharmaceutica N.V. |
Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives
|
EP1261343A2
(en)
*
|
2000-02-29 |
2002-12-04 |
Janssen Pharmaceutica N.V. |
Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives
|
EP1261356A2
(en)
*
|
2000-02-29 |
2002-12-04 |
Janssen Pharmaceutica N.V. |
Farnesyl protein transferase inhibitor combinations with platinum compounds
|
US6844357B2
(en)
*
|
2000-05-01 |
2005-01-18 |
Pfizer Inc. |
Substituted quinolin-2-one derivatives useful as antiproliferative agents
|
JO2361B1
(en)
|
2000-06-22 |
2006-12-12 |
جانسين فارماسيوتيكا ان. في |
Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
|
WO2002024683A1
(en)
*
|
2000-09-25 |
2002-03-28 |
Janssen Pharmaceutica N.V. |
Farnesyl transferase inhibiting 6-[(substituted phenyl)methyl]-quinoline and quinazoline derivatives
|
JP4974438B2
(ja)
|
2000-09-25 |
2012-07-11 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
ファルネシルトランスフェラーゼを阻害する6−ヘテロシクリルメチルキノリンおよびキナゾリン誘導体
|
US7053105B2
(en)
|
2000-09-25 |
2006-05-30 |
Janssen Pharmaceutica, N.V. |
Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors
|
JP4974439B2
(ja)
*
|
2000-09-25 |
2012-07-11 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
ファルネシルトランスフェラーゼを阻害する6−ヘテロシクリルメチルキノリノン誘導体
|
DE60139080D1
(de)
*
|
2000-11-21 |
2009-08-06 |
Janssen Pharmaceutica Nv |
Farnesyltransferase hemmende benzoheterocyclische derivate
|
PT1339407E
(pt)
*
|
2000-11-28 |
2006-08-31 |
Janssen Pharmaceutica Nv |
Inibidores da proteina farnesil transferase para o tratamento de doenca inflamatoria do intestino
|
AU2002218436A1
(en)
*
|
2000-12-19 |
2002-07-01 |
Pfizer Products Inc. |
Crystal forms of 6-((4-chloro-phenyl) -hydroxy-(-3-methyl- 3h-imidaol-4-yl) -methyl) -4-(3-ethynyl-phenyl) -1-methyl-1h- quinolin-2-one, 2,3- dihydroxybutanedioate salts and method of production
|
DE60117847T2
(de)
|
2000-12-27 |
2006-11-16 |
Janssen Pharmaceutica N.V. |
Farnesyltransferase hemmende, in der 4-stellung substituierte chinolin- und chinazolinderivate
|
PT1351954E
(pt)
*
|
2000-12-27 |
2006-09-29 |
Janssen Pharmaceutica Nv |
Derivados 4-heterociclil-quinolina e quinazolina inibidores da farnesil-transferase
|
AU2002236813A1
(en)
*
|
2001-01-22 |
2002-07-30 |
Schering Corporation |
Treatment of malaria with farnesyl protein transferase inhibitors
|
ATE415161T1
(de)
*
|
2001-02-15 |
2008-12-15 |
Janssen Pharmaceutica Nv |
Farnesyl-protein-transferase hemmer in kombination mit antiöstrogenen
|
CZ300622B6
(cs)
*
|
2001-03-12 |
2009-07-01 |
Janssen Pharmaceutica N. V. |
Zpusob prípravy 4-(3-chlorfenyl)-6-[(4-chlorfenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-1-methyl-2(1H)-chinolinonu
|
US20020151563A1
(en)
*
|
2001-03-29 |
2002-10-17 |
Pfizer Inc. |
Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the inhibition of abnormal cell growth
|
WO2003000705A1
(en)
*
|
2001-06-21 |
2003-01-03 |
Ariad Pharmaceuticals, Inc. |
Novel quinolines and uses thereof
|
EP1408971A4
(en)
|
2001-06-21 |
2006-01-25 |
Ariad Pharma Inc |
NEW QUINOLINES AND THEIR USES
|
US6740757B2
(en)
|
2001-08-29 |
2004-05-25 |
Pfizer Inc |
Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer
|
US20030134846A1
(en)
*
|
2001-10-09 |
2003-07-17 |
Schering Corporation |
Treatment of trypanosoma brucei with farnesyl protein transferase inhibitors
|
AU2002358677B2
(en)
|
2001-12-19 |
2008-02-07 |
Janssen Pharmaceutica N.V. |
1,8-annelated quinoline derivatives substituted with carbon-linked triazoles as farnesyl transferase inhibitors
|
CA2478813C
(en)
*
|
2002-03-22 |
2011-10-18 |
Janssen Pharmaceutica N.V. |
Benzylimidazolyl substituted 2-quinoline and quinazoline derivatives for use as farnesyl transferase inhibitors
|
ATE336496T1
(de)
|
2002-04-15 |
2006-09-15 |
Janssen Pharmaceutica Nv |
Farnesyl transferase hemmende tricyclische quinazolinederivate substitutiert mit kohlenstoff-gebundenen imidazolen oder triazolen
|
US7132100B2
(en)
|
2002-06-14 |
2006-11-07 |
Medimmune, Inc. |
Stabilized liquid anti-RSV antibody formulations
|
US7425618B2
(en)
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
US20030125268A1
(en)
*
|
2002-08-28 |
2003-07-03 |
Rybak Mary Ellen Margaret |
Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
|
WO2004022097A1
(en)
*
|
2002-09-05 |
2004-03-18 |
Medimmune, Inc. |
Methods of preventing or treating cell malignancies by administering cd2 antagonists
|
US7563810B2
(en)
*
|
2002-11-06 |
2009-07-21 |
Celgene Corporation |
Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
|
US8034831B2
(en)
*
|
2002-11-06 |
2011-10-11 |
Celgene Corporation |
Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
|
EP1613273B1
(en)
|
2003-04-11 |
2012-06-13 |
MedImmune, LLC |
Recombinant il-9 antibodies and uses thereof
|
US20050003422A1
(en)
|
2003-07-01 |
2005-01-06 |
Mitch Reponi |
Methods for assessing and treating cancer
|
BRPI0412876A
(pt)
*
|
2003-07-22 |
2006-10-03 |
Janssen Pharmaceutica Nv |
derivados de quinolinona como inibidores de c-fms quinase
|
AU2004286198C1
(en)
|
2003-08-18 |
2011-02-24 |
Medimmune, Llc |
Humanization of antibodies
|
US20060228350A1
(en)
*
|
2003-08-18 |
2006-10-12 |
Medimmune, Inc. |
Framework-shuffling of antibodies
|
CN1856470A
(zh)
*
|
2003-09-23 |
2006-11-01 |
默克公司 |
喹啉钾通道抑制剂
|
WO2005089518A2
(en)
*
|
2004-03-18 |
2005-09-29 |
The Brigham And Women's Hospital, Inc. |
Uch-l1 expression and cancer therapy
|
US20050277629A1
(en)
*
|
2004-03-18 |
2005-12-15 |
The Brigham And Women's Hospital, Inc. |
Methods for the treatment of synucleinopathies (Lansbury)
|
US20070293539A1
(en)
*
|
2004-03-18 |
2007-12-20 |
Lansbury Peter T |
Methods for the treatment of synucleinopathies
|
CA2559282A1
(en)
*
|
2004-03-18 |
2005-09-29 |
Brigham And Women's Hospital, Inc. |
Methods for the treatment of synucleinopathies
|
WO2005089504A2
(en)
*
|
2004-03-18 |
2005-09-29 |
The Brigham And Women's Hospital, Inc. |
Methods for the treatment of synucleinopathies
|
WO2005089515A2
(en)
*
|
2004-03-18 |
2005-09-29 |
The Brigham And Women's Hospital, Inc. |
Methods for the treatment of synucleinopathies
|
JP5008554B2
(ja)
*
|
2004-05-03 |
2012-08-22 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
イミダゾール化合物の製造用のジアステレオ選択的合成方法
|
JP4917022B2
(ja)
*
|
2004-05-03 |
2012-04-18 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
6−ブロモ−4−(3−クロロフェニル)−2−メトキシ−キノリンを用いるジアステレオ選択的合成方法
|
ATE398612T1
(de)
|
2004-05-03 |
2008-07-15 |
Janssen Pharmaceutica Nv |
Diastereoselektive addition von lithiiertem n- methylimidazol an sulfinimine
|
CA2571421A1
(en)
|
2004-06-24 |
2006-01-05 |
Nicholas Valiante |
Compounds for immunopotentiation
|
GB0420722D0
(en)
*
|
2004-09-17 |
2004-10-20 |
Addex Pharmaceuticals Sa |
Novel allosteric modulators
|
EP1809326A4
(en)
|
2004-10-27 |
2009-11-04 |
Medimmune Inc |
MODULATION OF ANTIBODY SPECIFICITY BY MEASURING ADAPTATION OF ITS AFFINITY TO AN APPARENT ANTIGEN
|
ES2403060T3
(es)
|
2004-11-05 |
2013-05-13 |
Janssen Pharmaceutica Nv |
Uso terapéutico de inhibidores de la farnesiltransferasa y métodos de control de la eficacia de los mismos.
|
US20060194821A1
(en)
*
|
2005-02-18 |
2006-08-31 |
The Brigham And Women's Hospital, Inc. |
Compounds inhibiting the aggregation of superoxide dismutase-1
|
EP1869192B1
(en)
|
2005-03-18 |
2016-01-20 |
MedImmune, LLC |
Framework-shuffling of antibodies
|
EP1888050B1
(en)
|
2005-05-17 |
2012-03-21 |
Merck Sharp & Dohme Ltd. |
cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropanoic acid for the treatment of cancer
|
US20060281769A1
(en)
*
|
2005-06-10 |
2006-12-14 |
Baumann Christian A |
Synergistic modulation of flt3 kinase using thienopyrimidine and thienopyridine kinase modulators
|
US20060281755A1
(en)
*
|
2005-06-10 |
2006-12-14 |
Baumann Christian A |
Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators
|
US20060281788A1
(en)
*
|
2005-06-10 |
2006-12-14 |
Baumann Christian A |
Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
|
US20070004660A1
(en)
*
|
2005-06-10 |
2007-01-04 |
Baumann Christian A |
Synergistic Modulation of Flt3 Kinase Using Alkylquinolines and Alkylquinazolines
|
WO2007002543A2
(en)
|
2005-06-23 |
2007-01-04 |
Medimmune, Inc. |
Antibody formulations having optimized aggregation and fragmentation profiles
|
WO2007110709A2
(en)
*
|
2005-10-14 |
2007-10-04 |
Janssen Pharmaceutica, N.V. |
Formulations of tipifarnib for intravenous administration
|
CA2634598A1
(en)
|
2005-12-23 |
2007-07-05 |
Link Medicine Corporation |
Treatment of synucleinopathies
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
AR059898A1
(es)
|
2006-03-15 |
2008-05-07 |
Janssen Pharmaceutica Nv |
Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
|
AR060358A1
(es)
|
2006-04-06 |
2008-06-11 |
Novartis Vaccines & Diagnostic |
Quinazolinas para la inhibicion de pdk 1
|
US7414050B2
(en)
|
2006-04-20 |
2008-08-19 |
Janssen Pharmaceutica, N.V. |
Inhibitors of c-fms kinase
|
CA2649739C
(en)
|
2006-04-20 |
2015-09-01 |
Janssen Pharmaceutica N.V. |
Inhibitors of c-fms kinase
|
US8697716B2
(en)
|
2006-04-20 |
2014-04-15 |
Janssen Pharmaceutica Nv |
Method of inhibiting C-KIT kinase
|
TW201343676A
(zh)
|
2006-08-28 |
2013-11-01 |
Kyowa Hakko Kirin Co Ltd |
具拮抗性之人類light專一性人類單株抗體
|
EP2698157B1
(en)
|
2006-09-22 |
2015-05-20 |
Merck Sharp & Dohme Corp. |
Method of treatment using fatty acid synthesis inhibitors
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
KR101591656B1
(ko)
|
2007-01-10 |
2016-02-19 |
엠에스디 이탈리아 에스.알.엘. |
폴리(adp-리보오스) 폴리머라아제(parp) 억제제로서의 아미드 치환된 인다졸
|
US8822497B2
(en)
|
2007-03-01 |
2014-09-02 |
Novartis Ag |
PIM kinase inhibitors and methods of their use
|
TW200900065A
(en)
|
2007-03-07 |
2009-01-01 |
Janssen Pharmaceutica Nv |
3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
|
TW200845978A
(en)
|
2007-03-07 |
2008-12-01 |
Janssen Pharmaceutica Nv |
3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
|
EP2703007A1
(en)
|
2007-03-30 |
2014-03-05 |
MedImmune, LLC |
Antibodies with decreased deamidation profiles
|
JO2959B1
(en)
|
2007-05-14 |
2016-03-15 |
جانسين فارماسوتيكا ان. في |
Mono-hydrochloric salts for histone dacetylase inhibitor
|
EP2152700B1
(en)
|
2007-05-21 |
2013-12-11 |
Novartis AG |
Csf-1r inhibitors, compositions, and methods of use
|
JP2010528034A
(ja)
*
|
2007-05-23 |
2010-08-19 |
アラーガン、インコーポレイテッド |
医薬としての((フェニル)イミダゾリル)メチルキノリニル化合物
|
US8389553B2
(en)
|
2007-06-27 |
2013-03-05 |
Merck Sharp & Dohme Corp. |
4-carboxybenzylamino derivatives as histone deacetylase inhibitors
|
ES2356032T3
(es)
|
2007-09-14 |
2011-04-04 |
Ortho-Mcneil-Janssen Pharmaceuticals, Inc. |
4-fenil-3,4,5,6-tetrahidro-2h,1'h-[1,4']bipiridinil-2'-onas 1,3'-disustituidas.
|
TW200922566A
(en)
|
2007-09-14 |
2009-06-01 |
Ortho Mcneil Janssen Pharm |
1,3 disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones
|
JO3240B1
(ar)
|
2007-10-17 |
2018-03-08 |
Janssen Pharmaceutica Nv |
c-fms مثبطات كيناز
|
MX2010004374A
(es)
|
2007-10-31 |
2010-04-30 |
Medimmune Llc |
Armazones proteinicos.
|
JP2011517313A
(ja)
|
2007-12-11 |
2011-06-02 |
ビアメト ファーマシューティカルズ,インク. |
金属結合部分を標的化部分と組み合わせて使用する金属酵素阻害剤
|
KR20100093129A
(ko)
|
2007-12-20 |
2010-08-24 |
노파르티스 아게 |
Pi 3 키나제 억제제로서 사용되는 티아졸 유도체
|
US7932036B1
(en)
|
2008-03-12 |
2011-04-26 |
Veridex, Llc |
Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase
|
WO2009151683A2
(en)
*
|
2008-03-12 |
2009-12-17 |
Link Medicine Corporation |
Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
|
MX2011002042A
(es)
|
2008-09-02 |
2011-06-20 |
Ortho Mcneil Janssen Pharm |
Derivados de 3-azabiciclo[3.1.o]hexilo como moduladores de los receptores del glutamato metabotropico.
|
US20110060005A1
(en)
*
|
2008-11-13 |
2011-03-10 |
Link Medicine Corporation |
Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
|
WO2010057028A2
(en)
*
|
2008-11-13 |
2010-05-20 |
Link Medicine Corporation |
Treatment of proteinopathies using a farnesyl transferase inhibitor
|
JP2012508768A
(ja)
*
|
2008-11-13 |
2012-04-12 |
リンク・メディスン・コーポレーション |
アザキノリノン誘導体及びその使用
|
US20100331363A1
(en)
*
|
2008-11-13 |
2010-12-30 |
Link Medicine Corporation |
Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
|
EP2373649B1
(en)
|
2008-11-28 |
2013-01-23 |
Janssen Pharmaceuticals, Inc. |
Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
|
WO2010114780A1
(en)
|
2009-04-01 |
2010-10-07 |
Merck Sharp & Dohme Corp. |
Inhibitors of akt activity
|
MY153913A
(en)
|
2009-05-12 |
2015-04-15 |
Janssen Pharmaceuticals Inc |
7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
|
NZ596053A
(en)
|
2009-05-12 |
2013-05-31 |
Janssen Pharmaceuticals Inc |
1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
|
MX2011011964A
(es)
|
2009-05-12 |
2012-02-23 |
Janssen Pharmaceuticals Inc |
Derivados de 1,2,3-triazolo[4,3-a]piridina y su uso para el tratamiento o prevencion de trastornos neurologicos y psiquiatricos.
|
JP6073677B2
(ja)
|
2009-06-12 |
2017-02-01 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
縮合複素環式化合物およびそれらの使用
|
US8293753B2
(en)
|
2009-07-02 |
2012-10-23 |
Novartis Ag |
Substituted 2-carboxamide cycloamino ureas
|
MX2012004377A
(es)
|
2009-10-14 |
2012-06-01 |
Merck Sharp & Dohme |
Piperidinas sustituidas que aumentan la actividad de p53 y sus usos.
|
CA2784807C
(en)
|
2009-12-29 |
2021-12-14 |
Dana-Farber Cancer Institute, Inc. |
Type ii raf kinase inhibitors
|
AU2011227643A1
(en)
|
2010-03-16 |
2012-09-20 |
Dana-Farber Cancer Institute, Inc. |
Indazole compounds and their uses
|
EP2584903B1
(en)
|
2010-06-24 |
2018-10-24 |
Merck Sharp & Dohme Corp. |
Novel heterocyclic compounds as erk inhibitors
|
ES2705719T3
(es)
|
2010-07-28 |
2019-03-26 |
Janssen Diagnostics Llc |
Métodos de determinación de la respuesta de la leucemia mieloide aguda al tratamiento con inhibidores de la farnesiltransferasa
|
AR082418A1
(es)
|
2010-08-02 |
2012-12-05 |
Novartis Ag |
Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
|
US8518907B2
(en)
|
2010-08-02 |
2013-08-27 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
|
EP3587574B1
(en)
|
2010-08-17 |
2022-03-16 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina)
|
US8883801B2
(en)
|
2010-08-23 |
2014-11-11 |
Merck Sharp & Dohme Corp. |
Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
|
EP2613782B1
(en)
|
2010-09-01 |
2016-11-02 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as erk inhibitors
|
WO2012036997A1
(en)
|
2010-09-16 |
2012-03-22 |
Schering Corporation |
Fused pyrazole derivatives as novel erk inhibitors
|
US9260471B2
(en)
|
2010-10-29 |
2016-02-16 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
|
JP5852666B2
(ja)
|
2010-11-08 |
2016-02-03 |
ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド |
1,2,4−トリアゾロ[4,3−a]ピリジン誘導体およびmGluR2受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
|
US9012448B2
(en)
|
2010-11-08 |
2015-04-21 |
Janssen Pharmaceuticals, Inc. |
1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
|
EP2649069B1
(en)
|
2010-11-08 |
2015-08-26 |
Janssen Pharmaceuticals, Inc. |
1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
|
US9351965B2
(en)
|
2010-12-21 |
2016-05-31 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as ERK inhibitors
|
AR085091A1
(es)
|
2011-01-26 |
2013-09-11 |
Kolltan Pharmaceuticals Inc |
Anticuerpos anti-kit y sus usos
|
JP5963777B2
(ja)
|
2011-01-31 |
2016-08-03 |
ノバルティス アーゲー |
新規ヘテロ環誘導体
|
AU2012245971A1
(en)
|
2011-04-21 |
2013-10-17 |
Piramal Enterprises Limited |
A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
|
WO2013063214A1
(en)
|
2011-10-27 |
2013-05-02 |
Merck Sharp & Dohme Corp. |
Novel compounds that are erk inhibitors
|
CN104039790B
(zh)
|
2011-10-28 |
2016-04-13 |
诺华股份有限公司 |
嘌呤衍生物及它们在治疗疾病中的应用
|
EP2822935B1
(en)
|
2011-11-17 |
2019-05-15 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of c-jun-n-terminal kinase (jnk)
|
EP3919620A1
(en)
|
2012-05-02 |
2021-12-08 |
Sirna Therapeutics, Inc. |
Short interfering nucleic acid (sina) compositions
|
BR112014028420A2
(pt)
|
2012-05-16 |
2017-09-19 |
Novartis Ag |
regime de dosagem para um inibidor de quinase pi-3
|
DK3381943T3
(da)
|
2012-07-25 |
2022-05-16 |
Celldex Therapeutics Inc |
Anti-kit-antistoffer og anvendelser deraf
|
JOP20180012A1
(ar)
|
2012-08-07 |
2019-01-30 |
Janssen Pharmaceutica Nv |
عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
|
EP2882757B1
(en)
|
2012-08-07 |
2016-10-05 |
Janssen Pharmaceutica, N.V. |
Process for the preparation of heterocyclic ester derivatives
|
MX2015004041A
(es)
|
2012-09-28 |
2015-07-06 |
Merck Sharp & Dohme |
Compuestos novedosos que son inhibidores de erk.
|
CA2887129A1
(en)
|
2012-10-09 |
2014-04-17 |
Igenica, Inc. |
Anti-c16orf54 antibodies and methods of use thereof
|
WO2014062658A1
(en)
|
2012-10-16 |
2014-04-24 |
Janssen Pharmaceutica Nv |
Methylene linked quinolinyl modulators of ror-gamma-t
|
BR112015008515A2
(pt)
|
2012-10-16 |
2017-07-04 |
Janssen Pharmaceutica Nv |
moduladores de ror t de quinolinila ligada à heteroarila
|
EP2909193B1
(en)
|
2012-10-16 |
2017-04-19 |
Janssen Pharmaceutica NV |
Phenyl linked quinolinyl modulators of ror-gamma-t
|
EP2909194A1
(en)
|
2012-10-18 |
2015-08-26 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
US10000483B2
(en)
|
2012-10-19 |
2018-06-19 |
Dana-Farber Cancer Institute, Inc. |
Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
|
WO2014063061A1
(en)
|
2012-10-19 |
2014-04-24 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged small molecules as inducers of protein degradation
|
CA2892361A1
(en)
|
2012-11-28 |
2014-06-05 |
Merck Sharp & Dohme Corp. |
Use of a wee1 inhibitor for treating a cancer characterized by low pkmyt1 expression levels
|
ES2707305T3
(es)
|
2012-12-20 |
2019-04-03 |
Merck Sharp & Dohme |
Imidazopiridinas sustituidas como inhibidores de HDM2
|
WO2014120748A1
(en)
|
2013-01-30 |
2014-08-07 |
Merck Sharp & Dohme Corp. |
2,6,7,8 substituted purines as hdm2 inhibitors
|
JO3368B1
(ar)
|
2013-06-04 |
2019-03-13 |
Janssen Pharmaceutica Nv |
مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
|
WO2014197849A2
(en)
|
2013-06-06 |
2014-12-11 |
Igenica Biotherapeutics, Inc. |
Anti-c10orf54 antibodies and uses thereof
|
EP3906945A3
(en)
|
2013-08-26 |
2022-03-16 |
BioNTech Research and Development, Inc. |
Nucleic acids encoding human antibodies to sialyl-lewis a
|
EP3041938A1
(en)
|
2013-09-03 |
2016-07-13 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
JO3367B1
(ar)
|
2013-09-06 |
2019-03-13 |
Janssen Pharmaceutica Nv |
مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
|
US9403816B2
(en)
|
2013-10-15 |
2016-08-02 |
Janssen Pharmaceutica Nv |
Phenyl linked quinolinyl modulators of RORγt
|
US9284308B2
(en)
|
2013-10-15 |
2016-03-15 |
Janssen Pharmaceutica Nv |
Methylene linked quinolinyl modulators of RORγt
|
US9221804B2
(en)
|
2013-10-15 |
2015-12-29 |
Janssen Pharmaceutica Nv |
Secondary alcohol quinolinyl modulators of RORγt
|
KR20160068956A
(ko)
|
2013-10-15 |
2016-06-15 |
얀센 파마슈티카 엔.브이. |
RORyT의 퀴놀리닐 조절제
|
KR20160070133A
(ko)
|
2013-10-15 |
2016-06-17 |
얀센 파마슈티카 엔.브이. |
RORyt의 알킬 결합 퀴놀리닐 조절제
|
US9328095B2
(en)
|
2013-10-15 |
2016-05-03 |
Janssen Pharmaceutica Nv |
Heteroaryl linked quinolinyl modulators of RORgammat
|
US10555941B2
(en)
|
2013-10-15 |
2020-02-11 |
Janssen Pharmaceutica Nv |
Alkyl linked quinolinyl modulators of RORγt
|
CA2927917C
(en)
|
2013-10-18 |
2022-08-09 |
Syros Pharmaceuticals, Inc. |
Heteroaromatic compounds useful for the treatment of proliferative diseases
|
CN105849099B
(zh)
|
2013-10-18 |
2020-01-17 |
达纳-法伯癌症研究所股份有限公司 |
周期蛋白依赖性激酶7(cdk7)的多环抑制剂
|
JP2016539149A
(ja)
|
2013-12-06 |
2016-12-15 |
ノバルティス アーゲー |
アルファ−アイソフォーム選択的ホスファチジルイノシトール3−キナーゼ阻害剤の投薬レジメン
|
KR102414246B1
(ko)
|
2014-01-21 |
2022-06-27 |
얀센 파마슈티카 엔.브이. |
대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
|
LT3431106T
(lt)
|
2014-01-21 |
2021-02-10 |
Janssen Pharmaceutica Nv |
Deriniai, apimantys 2 potipio metabotropinio glutamaterginio receptoriaus teigiamus alosterinius moduliatorius arba ortosterinius agonistus, ir jų panaudojimas
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
WO2015164614A1
(en)
|
2014-04-23 |
2015-10-29 |
Dana-Farber Cancer Institute, Inc. |
Janus kinase inhibitors and uses thereof
|
WO2015164604A1
(en)
|
2014-04-23 |
2015-10-29 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged janus kinase inhibitors and uses thereof
|
US10076512B2
(en)
|
2014-05-01 |
2018-09-18 |
Eiger Biopharmaceuticals, Inc. |
Treatment of hepatitis delta virus infection
|
US11311519B2
(en)
|
2014-05-01 |
2022-04-26 |
Eiger Biopharmaceuticals, Inc. |
Treatment of hepatitis delta virus infection
|
KR102614642B1
(ko)
|
2014-06-04 |
2023-12-19 |
바이오엔테크 리서치 앤드 디벨롭먼트 인코포레이티드 |
강글리오사이드 gd2에 대한 사람 단클론 항체
|
JO3589B1
(ar)
|
2014-08-06 |
2020-07-05 |
Novartis Ag |
مثبطات كيناز البروتين c وطرق استخداماتها
|
EP3229838B1
(en)
|
2014-12-11 |
2020-09-09 |
Pierre Fabre Medicament |
Anti-c10orf54 antibodies and uses thereof
|
CA2972239A1
(en)
|
2014-12-23 |
2016-06-30 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
CN114504651A
(zh)
|
2015-03-03 |
2022-05-17 |
科马布有限公司 |
抗体、用途和方法
|
EP3273966B1
(en)
|
2015-03-27 |
2023-05-03 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
KR102514971B1
(ko)
|
2015-04-21 |
2023-03-27 |
아이거 바이오파마슈티컬스 인코포레이티드 |
로나파르닙 및 리토나버를 포함하는 약제 조성물
|
WO2016201370A1
(en)
|
2015-06-12 |
2016-12-15 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy of transcription inhibitors and kinase inhibitors
|
HUE049620T2
(hu)
|
2015-08-17 |
2020-09-28 |
Kura Oncology Inc |
Módszerek rákos páciensek kezelésére farneziltranszferáz inhibitorokkal
|
US9815790B2
(en)
|
2015-08-27 |
2017-11-14 |
Janssen Pharmaceutica Nv |
Chemically modified quinoline and quinolone derivatives useful as CB-1 inverse agonists
|
CA2996978A1
(en)
|
2015-09-09 |
2017-03-16 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
AU2016347881A1
(en)
|
2015-11-02 |
2018-05-10 |
Novartis Ag |
Dosage regimen for a phosphatidylinositol 3-kinase inhibitor
|
US10875920B2
(en)
|
2015-12-02 |
2020-12-29 |
Stcube & Co., Inc. |
Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereof
|
WO2017096017A1
(en)
|
2015-12-02 |
2017-06-08 |
Stsciences, Inc. |
Antibodies specific to glycosylated btla (b- and t- lymphocyte attenuator)
|
JOP20190055A1
(ar)
|
2016-09-26 |
2019-03-24 |
Merck Sharp & Dohme |
أجسام مضادة ضد cd27
|
WO2018060833A1
(en)
|
2016-09-27 |
2018-04-05 |
Novartis Ag |
Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
|
WO2018083248A1
(en)
|
2016-11-03 |
2018-05-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
ES2863730T3
(es)
|
2016-11-03 |
2021-10-11 |
Kura Oncology Inc |
Inhibidores de la farnesiltransferasa para uso en el tratamiento del cáncer
|
WO2018103027A1
(zh)
|
2016-12-08 |
2018-06-14 |
杭州领业医药科技有限公司 |
替吡法尼的晶型及其制备方法及药物组合物
|
JP7160833B2
(ja)
|
2017-04-13 |
2022-10-25 |
サイロパ ビー.ブイ. |
抗sirpアルファ抗体
|
KR20200015602A
(ko)
|
2017-05-31 |
2020-02-12 |
주식회사 에스티큐브앤컴퍼니 |
Btn1a1에 면역특이적으로 결합하는 항체 및 분자 및 이의 치료적 용도
|
CA3065300A1
(en)
|
2017-05-31 |
2018-12-06 |
Stcube & Co., Inc. |
Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1
|
CN110997724A
(zh)
|
2017-06-06 |
2020-04-10 |
斯特库伯株式会社 |
使用结合btn1a1或btn1a1-配体的抗体和分子治疗癌症的方法
|
US11707522B2
(en)
|
2017-10-13 |
2023-07-25 |
Boehringer Ingelheim International Gmbh |
Human antibodies to Tn antigen
|
WO2019094311A1
(en)
|
2017-11-08 |
2019-05-16 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
WO2019113269A1
(en)
|
2017-12-08 |
2019-06-13 |
Kura Oncology, Inc. |
Methods of treating cancer patients with farnesyltransferase inhibitors
|
WO2019148412A1
(en)
|
2018-02-01 |
2019-08-08 |
Merck Sharp & Dohme Corp. |
Anti-pd-1/lag3 bispecific antibodies
|
KR20210039987A
(ko)
|
2018-05-18 |
2021-04-12 |
쿠라 온콜로지, 인크. |
티피파닙의 합성
|
MA53160A
(fr)
|
2018-07-20 |
2021-05-26 |
Pf Medicament |
Récepteur pour vista
|
US11981701B2
(en)
|
2018-08-07 |
2024-05-14 |
Merck Sharp & Dohme Llc |
PRMT5 inhibitors
|
WO2020033282A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
WO2020190604A1
(en)
|
2019-03-15 |
2020-09-24 |
Kura Oncology, Inc. |
Methods of treating cancer patients with farnesyltransferase inhibitors
|
CA3234276A1
(en)
*
|
2021-11-30 |
2023-06-08 |
Kura Oncology, Inc. |
Macrocyclic compounds having farnesyltransferase inhibitory activity
|
WO2023141082A1
(en)
*
|
2022-01-20 |
2023-07-27 |
Teva Czech Industries S.R.O. |
Solid state forms of tipifarnib and process for preparation thereof
|